[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

Clinical Observation of the Patients with Oral Adverse Events During Cancer Chemotherapy Including Molecular Targeted Drugs

  • AKIYAMA Kaoru
    Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
  • SAITO Masahiro
    Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
  • KOMIYAMA Yuske
    Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
  • TSUCHIDA Shuji
    Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
  • OKUBO Maki
    Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
  • KAWAMATA Hitoshi
    Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine

Bibliographic Information

Other Title
  • 分子標的治療薬を含むがん化学療法施行中の口腔内有害事象発症例の検討
  • ブンシ ヒョウテキ チリョウヤク オ フクム ガン カガク リョウホウ シコウ ナカノクチ クウナイ ユウガイ ジショウ ハッショウレイ ノ ケントウ

Search this article

Abstract

There was a few study concerning the oral adverse events during cancer therapy with molecular targeted drugs. Among the patients referred to our oral care unit from April 2007 to March 2014, 23 patients who were treated with molecular targeted drugs showed 27 oral adverse events. We examined the details of the oral adverse events and the causal drugs on these 23 patients. Ten patients were treated with small molecule drugs, while 17 patients were treated with monoclonal antibody drugs. The small molecule drugs were used singly, whereas the monoclonal antibody drugs were always used with conventional cytotoxic chemotherapeutic agents. Oral mucositis was observed in all 23 patients (27 events), and taste disorder was seen in 4 patients (4 events). All patients received the professional oral management, then they completed their cancer chemotherapy in the designated period. Because the single use of sunitinib (multi-kinase inhibitor) could lead oral mucositis, an intensive oral management before sunitinib treatment should be necessary.

Journal

Citations (0)*help

See more

References(0)*help

See more

Related Articles

See more

Related Data

See more

Related Books

See more

Related Dissertations

See more

Related Projects

See more

Related Products

See more

Details

Report a problem

Back to top